arrow
U

Ulrike K. Buchwald

Johns Hopkins Bloomberg School of Public Health
H指数:19
被引数:1,241

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18-49 Years of Age Enrolled at Center for Indigenous Health Sites

PNEU-DAY研究:一项随机III期临床试验,评估V114(一种15价PCV)随后6个月接种PPSV23的安全性、耐受性和免疫原性(在18-49岁于原住民健康中心注册的成人中的亚组分析)

2025-12-190
OA
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8

一项评估V116(一种成人专用肺炎球菌结合疫苗)在18-64岁肺炎球菌疫苗-naïve且罹患肺炎球菌疾病风险增加的成人中安全性、耐受性和免疫原性的III期随机试验,STRIDE-8

2025-11-010
OAAI
Correction: Omole et al. Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. Vaccines 2025, 13, 192

更正:Omole等人。23价肺炎球菌多糖疫苗(PPSV23)或15价肺炎球菌 conjugate 疫苗(PCV15)与mRNA-1273 SARS-CoV-2疫苗加强剂量在≥50岁健康成人中的安全性、耐受性和免疫原性。Vaccines 2025, 13, 192

2025-10-160
OAAI
The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay

肺炎球菌疫苗接种和鼻咽部定植对血清型特异性尿液抗原检测(SSUAD)试验性能的影响

Vaccine
IF3.5
2025-08-300
PRE
Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age

肺炎球菌疫苗PPSV23或PCV15与mRNA-1273 SARS-CoV-2疫苗加强剂量在 ≥ 50岁健康成人中的安全性、耐受性和免疫原性

2025-02-150
OAAI
Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3) : a randomised, double-blind, active comparator controlled, international phase 3 trial
2024-10-013
PRE
A Phase 3 randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability and immunogenicity of a 21-valent PCV, V116, in pneumococcal vaccine-naive adults (STRIDE-3)

一项3期随机,双盲,主动比较对照研究,以评估21价PCV V116在未接种肺炎球菌疫苗的成年人 (STRIDE-3) 中的安全性,耐受性和免疫原性

2024-01-030
OAAI
A Phase 3, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate Safety, Tolerability, and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Allogeneic Hematopoietic Cell Transplant Recipients (PNEU-STEM)
2023-06-206
OAAI
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors

3期试验评估V114的安全性,耐受性和免疫原性,15价肺炎球菌结合疫苗,6个月后23价肺炎球菌多糖疫苗,在18-49岁的高危成年人 (pneu-day): 基线风险因素的亚组分析

2023-03-024
OAAI